November 2019 Volume 15, Issue 11

Volume 15, Issue 11 | November 2019
November 2019
In this Issue
Clinical Trials

Reata’s omav shows its MOXIe
Investigational treatment for Friedreich’s ataxia leads to significant improvement in patient scores
Dynamic progress for diabetes
Two companies are making large strides in the diabetes realm
Riding the waves of Lonsurf
Taiho Oncology reports promising findings for patients with prior gastrectomy
A new idea with IDO
Phase 2 trial evaluates a new tool in pediatric cancer immunotherapyDiagnostics

Prostates and PARPs
Theragnostics makes moves on the prostate front
Transformative technology
Mount Sinai establishes institute for research and training
Betting on the future
Illumina, QIAGEN look to stake their claim on the NGS IVD market
Advancing nuclear medicine to treat cancer
Fuzionaire Diagnostics partners with Japan Medical Isotope Technology Development to launch new firmBusiness & Government Policy

It’s all in the delivery
Checking out the news in drug delivery advancements
Passing some gems to Emerald
Amarantus enters into agreement to license diverse therapeutics portfolio to CBD-focused company
On the cutting edge
A roundup of instrumentation, software and other tools and technology news
Pushing the envelope
Duke launches center to explore innovative science and technology policy
Major option for microinjector
Clearside announces option exercise by REGENXBIO for gene therapy delivery tech
Patent Docs: Sovereign immunity not absolute for states under the Eleventh Amendment
Kevin Noonan discusses a case in which the University of Texas sued Boston Scientific for patent infringement related to implantable drug-releasing biodegradable fibersEditor's Focus

Editor’s Focus: Organic is often good for you
It seems there might be a trend away from crude and opportunistic tack-on merger and acquisition deals and toward more deliberate M&A deals that better fit companies' current and future needs, which would be welcome in an era when internal, organic R&D growth isn't what it used to beFeature

2019 ASCB|EMBO Show Preview: A biologically dynamic duo
Year three of the collaborative ASCB|EMBO meeting presents a wide variety of innovative cell biology researchCommentary

Guest Commentary: Realizing the promise of microelectrode arrays
Improving throughput and reliability in routine neurotoxicity testing
Out of order: Not to be negative
The very fact that we define results as positive or negative highlights our reluctance to accept change, that the story we have built in our heads may not fully reflect our realityResearch & Development

Untangling the knot
USC researchers publish results in Cell Stem Cell that could prove the key to effective, reproducible cell reprogramming
Stanford on the mind
University teams make progress on rare CNS disease and identify a potential Parkinson’s biomarker
Improving the innovation lifecycle
CAS launches Formulus in effort to help fast-track product development
Calculating the risk
Elsevier and pharma industry leaders to build new drug-drug interaction risk calculatorContract Services

Gaining ground
QPS announces new clinics in three key areas for CRO market growth
They can’t ‘contain’ themselves
Burgeoning oncology pipeline increases demand for containment manufacturing, which is good news for many CMOs
Global workforce challenges for CROs
VIARES partners with ACRP to help address these issuesDiscovery

Building off of nature’s basics
New antibacterial tactic harnesses natural enzymes to kill bacteria
A mutual microbiome plan
Kaleido Biosciences collaborates with Gustave Roussy to develop Microbiome Metabolic Therapies
Emulating diabetes for drug discovery
Collaboration will develop three-dimensional models
New target for two tricky cancers
Blocking a specific protein reduces fibrosis and thwarts ovarian and pancreatic cancerPreclinical

Auransa advances AU-409
Company presents new preclinical data on its potential treatment for hepatocellular carcinoma
Joining hands on first-in-class cancer therapy
Ivy Brain Tumor Center and Salarius conduct preclinical study to test seclidemstat
Repurposed receptor
Drug is said to reduce pulmonary fibrosis by 56 percent
Biocon in-licenses early-stage biosimilar from Evotec
Company will undertake development, manufacturing and commercialization under its own label

Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
Subscribe